Colossal Biosciences
Gene editing to revive extinct species
Biotech
📍 Dallas, Texas
Founded 2021
Current Valuation
$10B
as of 2025-Q1
DECACORN
Colossal Biosciences is a Dallas-based gene-editing company on a mission to revive extinct species, with active programs targeting the woolly mammoth, Tasmanian tiger (thylacine), and dodo bird. Co-founded by serial entrepreneur Ben Lamm and Harvard geneticist George Church, the company reached a $10.2B valuation in January 2025 with a $200M Series C led by TWG Global, becoming Texas's first decacorn. A $120M Series C extension followed in September 2025 with continued progress on avian de-extinction.
Company Profile
Growth
Texas's first decacorn; $10.2B Series C valuation
Last Round
Series C extension — $120M (Sep 2025)
Founders & Key People
Ben LammGeorge Church
Investors
TWG Global · USIT · Robert Nelsen · Bob Iger · Tim Draper · Tom Brady · Paris Hilton · Animoca Brands · In-Q-Tel · Breyer Capital · Thomas Tull
Products
- Woolly mammoth revival program
- Tasmanian tiger (thylacine) revival
- Dodo bird revival
- Spinoff: Form Bio (computational biology)
- Spinoff: Breaking (plastic-degrading enzymes)
Competitors
Ginkgo Bioworks · Twist Bioscience · Editas Medicine · Genus plc
De-extinctionGene editingCRISPRSynthetic biologyDecacornConservation biotech
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q1. Refreshed quarterly.